Progress in the treatment of neuroendocrine tumors

Current Oncology Reports

Volumn 11, Issue 3, 2009, Pages 193-199

  Chan, Jennifer A ^a   Kulke, Matthew H ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANGIOPEPTIN; BEVACIZUMAB; CAPECITABINE; CHLOROZOTOCIN; DACARBAZINE; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; INDIUM 111; LUTETIUM 177; OCTREOTIDE; PASIREOTIDE; RAPAMYCIN; SOMATOMEDIN; SOMATOSTATIN RECEPTOR; SORAFENIB; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; VASCULOTROPIN; YTTRIUM 90;

ADVANCED CANCER; BONE MARROW SUPPRESSION; CANCER INCIDENCE; CANCER RADIOTHERAPY; CARCINOID SYNDROME; CHEMOEMBOLIZATION; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DEPRESSION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG MECHANISM; FATIGUE; HUMAN; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; PREVALENCE; REVIEW; SIDE EFFECT; THYROID FUNCTION;

ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; HUMANS; INDOLES; NEUROENDOCRINE TUMORS; OCTREOTIDE; PANCREATIC NEOPLASMS; PYRROLES; RADIOPHARMACEUTICALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS;

EID: 65349128139     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-009-0028-0     Document Type: Review

References (49)

1. Modlin I, Sandor A: An analysis of 8305 cases of carcinoid tumors. Cancer 1997, 79: 813-829.
2. Yao JC, Hassan M, Phan A, et al.: One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008, 26: 3063-3072.
3. Kloppel G, Perren A, Heitz PU: The gastroenteropancreatic neuroendocrine cell system and its tumors: The WHO classification. Ann N Y Acad Sci 2004, 1014: 13-27.
4. Thorson A, Biorck G, Bjorkman G, et al.: Malignant carcinoid of the small intestine with metastases to the liver, valvular disease on the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis. Am Heart J 1954, 47: 795-817.
5. Sarmiento JM, Que FG: Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 2003, 12: 231-242.
6. Alsina AE, Bartus S, Hull D, et al.: Liver transplant for metastatic neuroendocrine tumor. J Clin Gastroenterol 1990, 12: 533-537.
7. Lang H, Oldhafer K, Weimann A, et al.: Liver transplantation for metastatic neuroendocrine tumors. Ann Surg 1997, 225: 347-354.
8. Le Treut YP, Delpero JR, Dousset B, et al.: Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg 1997, 225: 355-364.
9. Gupta S, Yao J, Ahrar K, et al.: Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: The MD Anderson experience. Cancer J 2003, 9: 261-267.
10. Loewe C, Schindl M, Cejna M, et al.: Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: Assessment of mid- and long-term results. AJR Am J Roentgenol 2003, 180: 1379-1384.
11. Moertel C, Johnson C, McKusick M, et al.: The management of patients with advanced carcinoid tumors and islet cell carcinoma. Ann Int Med 1994, 120: 302-309.
12. Rubin J, Ajani J, Schirmer W, et al.: Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999, 17: 600-606.
13. Kvols L, Moertel C, O'Connell M, et al.: Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin analog. N Engl J Med 1986, 315: 663-666.
14. O'Toole D, Ducreux M, Bommelaer G, et al.: Treatment of carcinoid syndrome: A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000, 88: 770-776.
15. Schmid HA, Schoeffter P: Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 2004, 80(Suppl 1): 47-50.
16. Kvols L, Wiedenmann B, Oberg K, et al.: Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a phase II study [abstract]. J Clin Oncol 2006, 24: 4082.
17. Frank M, Klose KJ, Wied M, et al.: Combination therapy with octreotide and alpha-interferon: Effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999, 94: 1381-1387.
18. Janson E, Oberg K: Long term management of the carcinoid syndrome: treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993, 32: 225-229.
19. Oberg K, Eriksson B: The role of interferons in the management of carcinoid tumors. Acta Oncol 1991, 30: 519-522.
20. Sun W, Lipsitz S, Catalano P, et al.: Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005, 23: 4897-4904.
21. Moertel C, Lefkopoulo M, Lipsitz S, et al.: Streptozocindoxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992, 326: 519-523.
22. Kouvaraki M, Ajani J, Hoff P, et al.: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004, 22: 4762-4771.
23. Stevens MF, Hickman JA, Langdon SP, et al.: Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987, 47: 5846-5852.
24. Kulke MH, Stuart K, Enzinger PC, et al.: Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006, 24: 401-406.
25. Kulke M, Stuart K, Earle C, et al.: A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors [abstract]. J Clin Oncol 2006, 24: 4044.
26. Ekeblad S, Sundin A, Janson ET, et al.: Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007, 13: 2986-2991.
27. Isacoff W, Moss R, Pecora A, et al.: Temozolomide/capecitabine therapy for metastatic neuroendocrine tumors of the pancreas. A retrospective review [abstract]. J Clin Oncol 2006, 24: 14023.
28. Strosberg J, Choie J, Gardner N, et al.: First-line treatment of metastatic endocrine carcinomas with capecitabine and temozolomide [abstract]. J Clin Oncol 2008, 26: 4612.
29. Krenning EP, Kwekkeboom DJ, Valkema R, et al.: Peptide receptor radionuclide therapy. Ann N Y Acad Sci 2004, 1014: 234-245.
30. Breeman WA, de Jong M, Kwekkeboom DJ, et al.: Somatostatin receptor-mediated imaging and therapy: Basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001, 28: 1421-1429.
31. Teunissen JJ, Kwekkeboom DJ, de Jong M, et al.: Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 2005, 19: 595-616.
32. Anthony LB, Woltering EA, Espenan GD, et al.: Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002, 32: 123-132.
33. DeJong M, Valkema R, Jamar F, et al.: Somatostatin-receptor targeted radionucleotide therapy of tumors: Preclinical and clinical findings. Semin Nucl Med 2002, 32: 133-140.
34. Virgolini I, Britton K, Buscombe J, et al.: In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002, 32: 148-155.
35. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al.: Radiolabeled somatostatin analog [177 Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005, 23: 2754-2762.
36. Kwekkeboom DJ, de Herder WW, Kam BL, et al.: Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008, 26: 2124-2130.
37. Terris B, Scoazec J, Rubbia L: Expression of vascular endothelial growth factor in digestive neuroendocrine tumors. Histopathology 1998, 32: 133-138.
38. Christofori G, Naik P, Hanahan D: Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol 1995, 9: 1760-1770.
39. La Rosa S, Uccella S, Finzi G, et al.: Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: Correlation with microvessel density and clinicopathologic features. Hum Pathol 2003, 34: 18-27.
40. Yao JC, Phan A, Hoff PM, et al.: Targeting vascular endothelial growth factor in advanced carcinoid tumor: A random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008, 26: 1316-1323.
41. Hobday TJ, Rubin J, Holen K, et al.: MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study [abstract]. J Clin Oncol 2007, 25: 4504.
42. Kulke MH, Lenz HJ, Meropol NJ, et al.: Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008, 26: 3403-3410.
43. Vignot S, Faivre S, Aguirre D, et al.: MTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005, 16: 525-537.
44. Podsypanina K, Lee RT, Politis C, et al.: An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/-mice. Proc Natl Acad Sci U S A 2001, 98: 10320-10325.
45. Wang L, Ignat A, Axiotis CA: Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Appl Immunohistochem Mol Morphol 2002, 10: 139-146.
46. Smolewski P: Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 2006, 17: 487-494.
47. Duran I, Kortmansky J, Singh D, et al.: A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006, 95: 1148-1154.
48. Yao JC, Phan AT, Chang DZ, et al.: Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: Results of a phase II study. J Clin Oncol 2008, 26: 4311-4318.
49. Ramanathan RK, Cnaan A, Hahn RG, et al.: Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 2001, 12: 1139-1143.